DiaMedica Therapeutics (DMAC) Prepaid Assets (2017 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Prepaid Assets came in at $567000.0 in Q2 2026, down 16.62% on a YoY basis from $680000.0 in Q2 2025, and down 22.44% quarter-over-quarter from $731000.0 in Q1 2026.
Analysis
DiaMedica Therapeutics (DMAC) Prepaid Assets (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Prepaid Assets for 10 consecutive years, with $567000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets fell 16.62% year-over-year to $567000.0; the trailing twelve-month figure through Jun 2026 stood at $567000.0 (down 16.62% YoY), and the FY2025 full-year result was $481000.0, up 111.89% from the prior year.
- Prepaid Assets eased to $567000.0 in Q2 2026 per DMAC's latest filing, from $731000.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $1.1 million in Q3 2023 and bottomed at $227000.0 in Q4 2024.
- Historically, Prepaid Assets has averaged $569777.8 across 5 years, with a median of $567500.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets surged 245.03% in 2023, then sank 74.8% in 2024.
- Over 5 years, Prepaid Assets stood at $251000.0 in 2022, then jumped by 63.75% to $411000.0 in 2023, then sank by 44.77% to $227000.0 in 2024, then surged by 111.89% to $481000.0 in 2025, then rose by 17.88% to $567000.0 in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $567000.0, $731000.0, and $481000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.47 Bn | 193.48 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.76 Bn | 175.58 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.10 Bn | 55.91 Bn | 1.37 Bn |
| 6 | Moderna | 53.44 Bn | 48.30 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.55 Bn | 30.24 Bn | 992.69 Mn |
| 8 | Biogen | 31.67 Bn | 30.39 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.63 Bn | 29.63 Bn | 1.16 Mn |
| 10 | DiaMedica Therapeutics | 351.39 Mn | 351.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 567,000.00 |
| Mar 31, 2026 | 731,000.00 |
| Dec 31, 2025 | 481,000.00 |
| Sep 30, 2025 | 445,000.00 |
| Jun 30, 2025 | 680,000.00 |
| Mar 31, 2025 | 649,000.00 |
| Dec 31, 2024 | 227,000.00 |
| Sep 30, 2024 | 280,000.00 |
| Jun 30, 2024 | 568,000.00 |
| Mar 31, 2024 | 569,000.00 |
| Dec 31, 2023 | 411,000.00 |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 675,000.00 |
| Mar 31, 2023 | 962,000.00 |
| Dec 31, 2022 | 251,000.00 |
| Sep 30, 2022 | 322,000.00 |
| Jun 30, 2022 | 534,000.00 |
| Mar 31, 2022 | 793,000.00 |
| Dec 31, 2021 | 197,000.00 |
| Sep 30, 2021 | 336,000.00 |